🧠 Pharmidex Launches GLP-Validated Intracranial Dosing for CNS
July 15, 2025
We’re excited to introduce our GLP-standard intracranial dosing platform delivering targeted compounds directly to the brain for more precise CNS preclinical studies.
✅ Bypasses the blood-brain barrier
✅ Reduces systemic side effects
✅ Enhances translational relevance
Now fully GLP-validated with:
Documented SOPs & equipment
Verified dose placement
MHRA-audited compliance
📈 Benefits: Regulatory-ready data, better reproducibility, and lower repeat study costs.
👉 Swipe the carousel to learn more.
🔗 www.pharmidex.com
#Pharmidex #IntracranialDosing #GLP #CNSResearch #DrugDelivery #PreclinicalStudies #MHRA #CRO
We’re pleased to share that Pharmidex has been selected as a partner in the EIC - European Innovation Council Ecosystem Partnership Programme. Our services are now featured on the EIC Service Catalogue, making them accessible to innovative companies and projects supported by the EIC across Europe. This is a great opportunity to further support cutting-edge biotech and life sciences programmes by providing: 🔬 Preclinical in vivo pharmacology 🧪 Bioanalysis (LC–MS/MS, qPCR, ELISA) 📊 Translational and mechanistic studies 🧫 Histology and pathology We look forward to working with EIC beneficiaries and contributing to the development of the next generation of therapies. If you are part of the EIC ecosystem and looking for a flexible, science-led CRO partner, we would be delighted to connect.
We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: 📄 “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" 📄 “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. 🔗 Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
